EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment

Eric J Lenze iD, Madeline Nykamp, J Philip Miller, Angela Stevens, Julia Schweiger iD, Torie Gettinger iD, Michael Yingling iD, Yi Zhang iD, Ginger E Nicol iD, Charles F Zorumski iD, Angela M Reiersen iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70292 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Eric J Lenze und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA. Hauptthemen laut MEDLINE: Fluvoxamine, COVID-19 Drug Treatment, Drug Monitoring. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials are increasingly using remote monitoring techniques at the patient's home. We conducted a secondary analysis of remote safety and tolerability monitoring from two fully‐remote clinical trials that tested fluvoxamine for the acute treatment of COVID‐19. Both trials assessed pulse and blood pressure daily, and one study assessed symptoms daily via Ecological Momentary Assessment. On average, patients provided data on vital signs on 93% of the study days and provided data on side effects on 81% of the study days. With respect to safety, patients taking fluvoxamine had reduced pulse rate compared to placebo, with the greatest difference—5 points—at treatment Day 4. In contrast, fluvoxamine showed little to no effect on blood pressure. With respect to tolerability, nausea was most frequent in the first 4–5 days, declining significantly thereafter, while anxiety and difficulty concentrating were uncommon with fluvoxamine compared to placebo. These findings show that remote assessment of safety and tolerability is feasible in clinical trials, and that frequent assessments can provide in‐depth data on the timecourse of safety or tolerability signals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluvoxamineCOVID-19 Drug TreatmentDrug MonitoringHumansMiddle AgedMaleFemaleSARS-CoV-2COVID-19AdultAgedBlood Pressure

Substanzen

Fluvoxamine

Autor:innen und Institutionen

  • Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA.

ORCID-Profile: Eric J Lenze, Julia Schweiger, Torie Gettinger, Michael Yingling, Yi Zhang, Ginger E Nicol, Charles F Zorumski, Angela M Reiersen

Zitieren

APA

Lenze, E. J., Nykamp, M., Miller, J. P., Stevens, A., Schweiger, J., Gettinger, T., Yingling, M., Zhang, Y., Nicol, G. E., Zorumski, C. F., & Reiersen, A. M. (2025). High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment. Clinical and Translational Science. https://doi.org/10.1111/cts.70292

Vancouver

Lenze EJ, Nykamp M, Miller JP, Stevens A, Schweiger J, Gettinger T, et al. High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment. Clinical and Translational Science. 2025. doi:10.1111/cts.70292

BibTeX
@article{Lenze2025,
  author = {Lenze, Eric J and Nykamp, Madeline and Miller, J Philip and Stevens, Angela and Schweiger, Julia and Gettinger, Torie and Yingling, Michael and Zhang, Yi and Nicol, Ginger E and Zorumski, Charles F and Reiersen, Angela M},
  title = {High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70292}
}
Kostenlos starten →